Drug updated on 7/25/2024
Dosage Form | Tablet (oral; 20 mg) |
Drug Class | Thrombopoietin receptor agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- Indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Latest News
Summary
- Avatrombopag (Doptelet) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure and those with chronic immune thrombocytopenia who have had an insufficient response to previous treatments.
- A total of 13 systematic reviews and meta-analyses were reviewed, focusing on avatrombopag's safety and effectiveness compared to other drugs.
- Avatrombopag shows superior efficacy in achieving overall and durable platelet response compared to eltrombopag and hetrombopag, with comparable results to romiplostim.
- The incidence of serious adverse events (AEs) in avatrombopag-treated patients does not significantly differ from placebo; however, overall AEs are slightly higher but do not increase the risk of thrombotic events significantly when compared to other TPO-RAs like romiplostim or eltrombopag.
- Most studies consider adult populations for both chronic immune thrombocytopenia and chronic liver disease. There is limited data involving children primarily focused on adults' evaluations.
- In preprocedural use for patients with chronic liver disease, avatrombopag effectively increases preoperative platelet counts while decreasing the need for platelet transfusions without increasing bleeding risks or thrombotic events.
- Combining TPO-RAs such as avatrombopag with other treatments like rituximab enhances therapeutic outcomes in severe ITP cases by achieving higher efficacy rates than monotherapy regimens alone.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Doptelet (avatrombopag) Prescribing Information. | 2021 | AkaRx, Inc., Durham, NC |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Australian public assessment report for doptelet. | 2024 | Australian Government Department of Health Therapeutic Goods Administration |
EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. | 2022 | Hemasphere |
Management of adult patients with immune thrombocytopenia (itp): a review on current guidance and experience from clinical practice. | 2021 | Journal of Blood Medicine |
Updated guidelines for immune thrombocytopenic purpura: expanded management options. | 2021 | Cleveland Clinic Journal of Medicine |
Practice guidelines of the Central European Hepatologic Ccollaboration (CEHC) on the use of thrombopoietin receptor agonists in patients with chronic liver disease undergoing invasive procedures. | 2021 | Journal of Clinical Medicine |
American Society of Hematology 2019 guidelines for immune thrombocytopenia. | 2019 | Blood Advances |